SCT and cyst: Evidence supports that somatostatin may blunt cyst development by acting at multiple levels: inhibition of secretin release by the pancreas [13], inhibition of secretin-induced cAMP generation and fluid secretion in cholangiocytes [14–16], vasopressin-induced cAMP generation and water permeability in collecting ducts by its effects on G protein-coupled receptors (Gi subtype), and suppression of the expression of IGF-1, vascular endothelial growth factor, and other cystogenic growth factors causing downstream signaling of their receptors [17–21].